Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (DE:LLY)
XETRA:LLY
Holding DE:LLY?
Track your performance easily
LLY Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€515.00 - €885.30
Previous Close€764.2
Volume1.06K
Average Volume (3M)3.90K
Market Cap
€689.48B
Enterprise Value€716.02B
Total Cash (Recent Filing)$3.52B
Total Debt (Recent Filing)$31.12B
Price to Earnings (P/E)86.4
Beta0.16
Next Earnings
Jan 30, 2025EPS Estimate
€5.26Next Dividend Ex-Date
Feb 14, 2025Dividend Yield0.69%
Share Statistics
EPS (TTM)8.46
Shares Outstanding949,315,694
10 Day Avg. Volume4,770
30 Day Avg. Volume3,897
Standard Deviation0.09
R-Squared0.00426
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)50.95
Price to Sales (P/S)17.84
Price to Cash Flow (P/CF)49.10
P/FCF Ratio77.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.52
Enterprise Value/Gross Profit26.48
Enterprise Value/Ebitda58.11
Forecast
1Y Price Target
€1,003.20Price Target Upside31.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Eli Lilly & Co News
PremiumThe Fly
Eli Lilly rises 6.3%
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageZepbound's superior weight loss results in the SURMOUNT-5 trial compared to Novo Nordisk's Wegovy could drive market share gains for Eli Lilly.
International Market OpportunitiesThe potential sales for obesity treatment in China are substantial and possibly underappreciated with a significant number of overweight and obese adults.
Product Approval And Market ExpansionTirzepatide could obtain approval for obstructive sleep apnea and heart failure, expanding its addressable market and Medicare coverage.
Bears Say
Earnings GuidanceThere is a concern about whether Eli Lilly can achieve its guidance for the fourth quarter, as it requires a significant increase in Mounjaro and Zepbound prescriptions.
Financial PerformanceLLY reported a miss driven by Mounjaro & Zepbound weakness, with a significant shortfall in their expected revenue.
Regulatory And Political RisksInvestors are worried about the potential impact of International Pricing Index getting implemented, affecting drug pricing.
---
Options Prices
Currently, No data available
---
Ownership Overview
10.35% Insiders
22.74% Mutual Funds
27.22% Other Institutional Investors
23.60% Public Companies and
Individual Investors
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was €515.00 and its highest was €885.30 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Currently, no data Available
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Jan 30, 2025 which is in 39 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Oct 30, 2024. The company reported €1.131 earnings per share for the quarter, missing the consensus estimate of €1.362 by -€0.231.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of €1.428 which represents an annual dividend yield of 0.69%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is €5.26.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 949,315,700 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of €1.131 in its last earnings report, missing expectations of €1.362. Following the earnings report the stock price went down -7.9%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Among the largest hedge funds holding Eli Lilly & Co’s share is PRIMECAP Management Co. It holds Eli Lilly & Co’s shares valued at 16B.
---
Eli Lilly & Co Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€1,003.20 (31.41% Upside)
€1,003.20 (31.41% Upside)
Blogger Sentiment
Bullish
DE:LLY Sentiment 85%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 56%
Bearish news 44%
Bearish news 44%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.52%
12-Months-Change
Fundamentals
Return on Equity
65.75%
Trailing 12-Months
Asset Growth
30.55%
Trailing 12-Months
Company Description
Eli Lilly & Co
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
---
LLY Company Deck
---
LLY Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and product performance, driven by new product launches and pipeline advancements. However, there were some challenges such as the decline in Trulicity revenue and inventory management issues impacting sales. Despite these, the company's financial health and future prospects remain robust.Read More>---
LLY Revenue Breakdown
84.44% Net product revenue
15.56% Collaboration and other revenue
---
LLY Stock 12 Month Forecast
Average Price Target
€1,003.20
▲(31.41% Upside)
Technical Analysis
Best Analysts Covering LLY
1 Year
1 Year Success Rate
32/37 ratings generated profit
1 Year Average Return
+35.82%
reiterated a buy rating 3 months ago
Copying Louise Chen's trades and holding each position for 1 Year would result in 86.49% of your transactions generating a profit, with an average return of +35.82% per trade.
---